Lack of Efficacy of Suvorexant in People with Insomnia and Poorly Controlled Type 2 Diabetes.

ABSTRACT:

Objective/background

Sleep disturbance is a common and underappreciated feature of diabetes and sleep may contribute to glycemic control in people with type 2 diabetes (T2D). We conducted a 3-month trial to examine the efficacy of suvorexant in improving sleep and health outcomes in people with suboptimally controlled T2D and insomnia.

Participants/methods

This parallel, double-blind, randomized placebo-controlled trial was conducted using the sequential parallel comparison design (SPCD). Sixty-nine people with poorly controlled T2D (HbA1c ≥ 6.5) were randomized to placebo and/or suvorexant (10-20 mg). The primary outcome was subjective total sleep time (sTST), and secondary outcomes were Insomnia Severity Index (ISI) score and wake time after sleep onset (WASO). Exploratory

SUBMITTER: Winkelman JW 

PROVIDER: S-EPMC10752032 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature